Onxeo Secures $7.5 Million of Non-dilutive Capital from SWK Holdings Corporation Through Sale of Rights related to Future Beleodaq® Royalties

Paris (France), June 7, 2018 – 07h00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs in oncology, notably against rare or resistant forms of cancer, today announced that it has entered into a royalty agreement with SWK Holdings Corporation, a US life science focused specialty finance company.

Under this agreement, Onxeo will immediately receive $7.5 million through the sale of bonds entitling SWK Holdings Corporation to receive $13.5 million of future royalties and milestones on sales of Beleodaq® (belinostat) in territories licensed to Spectrum Pharmaceuticals, Inc. Further details of the transaction were not disclosed.

Beleodaq® is a histone deacetylase inhibitor (‘HDAC inhibitor’) approved by the US Food and Drug Administration (‘FDA’) in July 2014 to treat refractory or relapsed PTCL. Beleodaq® is currently marketed by Spectrum Pharmaceuticals, Onxeo’s commercial partner in the US.

“We are pleased to have secured this transaction with SWK Holdings, a specialized healthcare investor,” said Nicolas Fellmann, CFO of Onxeo. “This capital will extend our cash runway until early 2020, without any dilution of our shareholders, and help drive the development of our key programs, notably AsiDNA™, through multiple significant inflection points during the next 12 to 18 months.”

“Beleodaq is an important treatment option for patients with refractory or relapsed PTCL,” said Winston Black, CEO of SWK Holdings. “We are pleased to partner with Onxeo on this transaction, helping Onxeo further advance its innovative oncology pipeline for the benefit of patients.”

Torreya Partners LLC acted as financial adviser and Goodwin Procter LLP acted as legal adviser to Onxeo on the transaction.

At March 31, 2018, the Company had €9.2 million in cash, not including the €3.7 million 2017 R&D tax credit that is expected to be received in the coming months.

Onxeo Reports Half-Year 2018 Financial Results and Provides Business Outlook• Clinical development of Onxeo’s lead product candidate AsiDNA™ progressing to plan o Preliminary safety and activity results of DRIIV-1 study are expected in Q4 2018o Two combination clinical trials with AsiDNA™ planned for early 2019• New optimized candidate from platON™ proprietary platform ready to enter preclinical stage by end 2018• Cash position of €11m at June 30, 2018 enables an expanded clinical development plan of AsiDNA™ into 2020The full press release in PDF

Paris, July 27, 2018 – 6:00 pm CEST - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today reported its consolidated half-year financial results[1], as of June 30, 2018 and provided a business update.

Judith Greciet, Chief Executive Officer of Onxeo, said: “The first half of 2018 was marked by an important step in the development of our lead product candidate AsiDNA™ as it entered a phase I clinical trial DRIIV-1 in patients with advanced solid tumors. We expect preliminary data in Q4 2018 which will confirm both the safety and systemic activity of this first-in-class DNA repair inhibitor. In parallel, we have conducted substantial preclinical work with AsiDNA™ in combination with other anticancer agents to assess its full potential. In that context, we have already obtained very compelling data regarding the synergistic effects and reversion of tumor resistance by AsiDNA™ when combined with a PARP inhibitor. Additional results on the interest of combining AsiDNA™ with belinostat have also been acquired and other experiments are ongoing to show the value of combining AsiDNA™ with carboplatin, a standard-of-care in chemotherapy. Together with the expected outcomes from the DRIIV-1 clinical study, this solid body of preclinical data opens a range of new clinical development opportunities to harvest the full potential of AsiDNA™ and we have planned already to broaden its development in combination as soon as 2019.

Furthermore, the extensive screening and optimization work on new molecules sourced from our PlatON™ platform is bearing fruit and we expect to advance the next optimized candidate into preclinical development by the end of the year, thereby enlarging Onxeo’s pipeline.

At this time and considering our available preclinical data, it appears that AsiDNA™ in combination with PARPi and/or carboplatin is the most promising option while belinostat could be best combined with a new candidate sourced from platON™, due to the respective pharmacokinetic properties of these assets.

During this half-year, we also strengthened our cash position with an equity line and the monetization of Beleodaq® royalties, to support the momentum of our development programs with this highly attractive technology in DNA targeting.”

[1] Half-year financial statements have been the subject of a limited review. The limited review report will be issued after the procedures required for the publication of the half-yearly financial report have been finalized.

About OnxeoOnxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a French biotechnology company developing innovative oncology drugs based on DNA-targeting and epigenetics, two of the most sought-after mechanisms of action in cancer treatment today. The Company is focused on bringing early-stage first-in-class or disruptive compounds (proprietary, acquired or in-licensed) from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.Onxeo is developing AsiDNA™, a first-in-class DNA break repair inhibitor based on a unique decoy mechanism. AsiDNA™ has already successfully completed a Phase I trial in metastatic melanoma via local administration and is currently being evaluated for systemic (IV) administration in solid tumors in the DRIIV-1 phase I study (DNA Repair Inhibitor administered IntraVenously).AsiDNA™ is the first compound generated from platON™, the Company’s proprietary chemistry platform of decoy oligonucleotides based on three components, a sequence of double strand oligonucleotides, a linker and a cellular uptake facilitator. PlatON™ will continue to generate innovative compounds targeting tumor DNA functions and broaden Onxeo’s pipeline.Onxeo’s R&D pipeline also includes belinostat, an HDAC inhibitor (epigenetics) currently evaluated in oral form to be used in combination with other anti-cancer agents for liquid or solid tumors. Belinostat is already conditionally FDA-approved in the US as a 2nd line treatment for patients with peripheral T cell lymphoma and marketed in the US by Onxeo’s partner, Spectrum Pharmaceuticals, under the name Beleodaq® (belinostat IV form).For further information, please visit www.onxeo.com.